Bioengineered blood vessel for Coronary Bypass Sustains 18-Month Patency — With a Full Year without Blood Thinners
News & Events Read our recent press releases and follow Vascudyne’s newest advancementsAugust 22, 2026 Bioengineered blood vessel for Coronary Bypass Sustains 18-Month Patency — With a Full Year without Blood Thinners Nature Communications study reports an...
Vascudyne Announces First European Clinical Implant for Coronary Artery Bypass
News & Events Read our recent press releases and follow Vascudyne’s newest advancementsApril 20th, 2026 Vascudyne Announces First European Clinical Implant for Coronary Artery BypassVascudyne is pleased to announce the publication of a new clinical case report...
First-in-Human Coronary Bypass Case Report Published in JACC: Case Reports
News & Events Read our recent press releases and follow Vascudyne’s newest advancementsMarch 24th 2026 First-in-Human Coronary Bypass Case Report Published in JACC: Case ReportsThis paper presents 12-month outcomes from the VCAB-1 study — the first clinical use of...
Vascudyne at the International Coronary Conference 2025
News & Events Read our recent press releases and follow Vascudyne’s newest advancementsDecember 11th 2025 Vascudyne at the International Coronary Conference 2025December 6–7, 2025 | New York, NY Vascudyne participated in the International Coronary Conference (ICC)...
Vascudyne Presented Groundbreaking Data on Bioengineered Vascular Graft at American Heart Association Scientific Sessions 2025
News & Events Read our recent press releases and follow Vascudyne’s newest advancementsNovember 8th 2025 Vascudyne to Present Groundbreaking Data on Bioengineered Vascular Graft at American Heart Association Scientific Sessions 2025First Bioengineered...
Vascudyne Presented Bioengineered Heart Valve Innovation at HVBTE Conference
News & Events Read our recent press releases and follow Vascudyne’s newest advancementsSeptember 18, 2025 Vascudyne Presented Bioengineered Heart Valve Innovation at HVBTE ConferenceExciting to share that Vascudyne's leadership team presented scientific updates on...
Vascudyne Medical Advisor Dr. Matt Soule Conducts Advanced VCAB-2 Training at Poznań Medical Institute
News & Events Read our recent press releases and follow Vascudyne’s newest advancementsJuly 15, 2025 Vascudyne Medical Advisor Dr. Matt Soule Conducts Advanced VCAB-2 Training at Poznań Medical InstitutePOZNAŃ, POLAND – Vascudyne announced that Dr. Matt Soule, the...
Vascudyne Awarded Prestigious DoD Translational Research Grant to Advance Growing Heart Valve Technology
News & Events Read our recent press releases and follow Vascudyne’s newest advancementsJune 1, 2025 Vascudyne Awarded Prestigious DoD Translational Research Grant to Advance Growing Heart Valve Technology$4M Award from Congressionally Directed Medical Research...
Vascudyne to Present Breakthrough Transcatheter Pulmonary Valve Research at Heart Valve Society Conference
News & Events Read our recent press releases and follow Vascudyne’s newest advancementsApril 15, 2025 Vascudyne to Present Breakthrough Transcatheter Pulmonary Valve Research at Heart Valve Society ConferenceThree Presentations Highlight 18-Month Preclinical Data...
Vascudyne Achieves Major Milestone with 18-Month Transcatheter Pulmonary Valve Study Published in Journal of the Heart Valve Society
News & Events Read our recent press releases and follow Vascudyne’s newest advancementsSeptember 18, 2025 Vascudyne Presented Bioengineered Heart Valve Innovation at HVBTE ConferenceExciting to share that Vascudyne's leadership team presented scientific updates on...
These are investigational uses that have not been approved by any health authority. Safety and efficacy have not been established and there is no guarantee that pipeline products or investigational uses will receive approval from health authorities.
Copyright 2025 | Vascudyne, Inc.






















